For US Healthcare Professionals
- Efficacy in PsO
- Safety Profile
- Mechanism of Action
- Support and Resources
- Efficacy in PsA
YEAR 1 TO YEAR 3
TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
VOYAGE 1: PRESPECIFIED SECONDARY ANALYSIS—RESULTS THROUGH YEAR 5* (AS-OBSERVED, GLOBAL ANALYSIS)†
In a prespecified secondary analysis of efficacy after Week 48 applying treatment failure rules (TFR)1:
Patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may increase the response rate in an as-observed analysis.
Data shown include patients randomized at Week 0 to TREMFYA® arm and placebo arm patients who crossed over to receive TREMFYA® at Weeks 16, 20, and q8w thereafter.
The same patients may not have responded at each time point.
TFR methods: Patients who discontinued study agent due to lack of efficacy or an adverse event of worsening of psoriasis, or who started a protocol-prohibited medication including conventional and biologic systemic therapy, phototherapy, and/or ultra–high-potency corticosteroids were considered treatment failures. Other topical agents for psoriasis were permitted.
*Year 5 represents Week 252.
†Available data at each visit were used; missing data were not included in the analysis.
‡Year 4 represents Week 204.
Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, United States and Canada]).
Reference: 1. Data on file. Janssen Biotech, Inc.